Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non-T790M mutations after progression on first-line EGFR-tyrosine kinase inhibitors.

Thorac Cancer · 2018 · PMC6119611 · PMID 30027579

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

20 Thus, the order in which bevacizumab plus chemotherapy and EGFR‐TKIs are administered to patients harboring EGFR mutations may be significant.

also in 11,575 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.